Wegovy Maker Novo Nordisk Pumps $6 Billion To Boost Production As Obesity Drug Rival Zepbound Is Approved
Novo has struggled to keep up with booming demand for its weight loss drug and said it could be years until it or its rivals are able to satisfy the growing market.
Novo has struggled to keep up with booming demand for its weight loss drug and said it could be years until it or its rivals are able to satisfy the growing market.
What's Your Reaction?
